Reassessing carbamazepine in the treatment of bipolar disorder: Clinical implications of new data

CNS Spectrums

Volumn 10, Issue 6, 2005, Pages 1-14

  Ginsberg, David L ^g   Akiskal, Hagop S ^a   Keck Jr , Paul E ^{e,f,g,i,k,l,n,o,q,r}   Fuller, Matthew A ^b,c,d,e,f,g   Weisler, Richard H ^s,t   Hirschfeld, Robert M A ^{e,f,g,h,i,j,k,l,m,n,o,p}   Hollander, Eric ^g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d UNIVERSITY OF TOLEDO   (United States)

^e ASTRAZENECA   (United Kingdom)

^f BRISTOL MYERS SQUIBB   (United States)

^g Eli Lilly ^*

^h University of Texas Medical Branch School of Medicine   (United States)

ⁱ ABBOTT LABORATORIES   (United States)

^j Forest   (United States)

^k GLAXOSMITHKLINE   (United Kingdom)

^l JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^m NOVARTIS   (Switzerland)

ⁿ Pfizer

^o Shire   (United States)

^p UCB PHARMA   (Belgium)

^q UNIVERSITY OF CINCINNATI   (United States)

^r OrthoMcNeil   (United States)

^s UNIVERSITY OF NORTH CAROLINA   (United States)

^t DUKE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; ANXIOLYTIC AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CENTRAL STIMULANT AGENT; CHLORPROMAZINE; CLOZAPINE; ETIRACETAM; FLUOXETINE; GABAPENTIN; HALOPERIDOL; IMMUNOSUPPRESSIVE AGENT; LAMOTRIGINE; LITHIUM; MUSCLE RELAXANT AGENT; NEUROLEPTIC AGENT; OLANZAPINE; OXCARBAZEPINE; PLACEBO; QUETIAPINE; RISPERIDONE; STEROID; TIAGABINE; TOPIRAMATE; VALPROATE SEMISODIUM; ZIPRASIDONE; ZONISAMIDE;

ACNE; AGRANULOCYTOSIS; AKATHISIA; APLASTIC ANEMIA; ATAXIA; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BLOOD CLOTTING DISORDER; BLOOD TOXICITY; CARDIOTOXICITY; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; CONFERENCE PAPER; CONSTIPATION; DIABETES MELLITUS; DIZZINESS; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG FORMULATION; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ELDERLY CARE; ERYTHEMA; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPONATREMIA; LIVER TOXICITY; LONG TERM CARE; MANIA; MONOTHERAPY; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; OVARY POLYCYSTIC DISEASE; PANCREATITIS; POLYPHARMACY; PRIORITY JOURNAL; PRURITUS; PSORIASIS; QT PROLONGATION; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SOMNOLENCE; SPEECH DISORDER; STEVENS JOHNSON SYNDROME; TERATOGENESIS; THYROID DISEASE; TOXIC EPIDERMAL NECROLYSIS; TREATMENT INDICATION; TREATMENT OUTCOME; TREMOR; VOMITING; WEIGHT GAIN; XEROSTOMIA;

EID: 21644450556     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/s1092852900023063     Document Type: Conference Paper

References (0)